Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium picosulfate is a small molecule stimulant laxative prodrug used primarily for bowel cleansing before colonoscopy or surgery, and for the treatment of constipation. Upon oral administration, it is hydrolyzed by colonic bacteria into its active metabolite, bis-(p-hydroxyphenyl)-pyridyl-2-methane (BHPM). BHPM acts locally in the large intestine to stimulate the enteric nervous system and colonic mucosa, leading to increased peristalsis and the secretion of water and electrolytes into the intestinal lumen. In clinical research conducted by Ahmed M Maged, MD at Cairo University, sodium picosulfate (administered as Picolax drops) is being studied in a Phase 4 trial to evaluate its efficacy in accelerating the recovery of bowel function and preventing postoperative ileus in patients following elective cesarean section.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium picosulfate.